These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7198328)

  • 1. Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer.
    Beckley S; Wajsman Z; Maeso E; Pontes E; Murphy G
    Urology; 1981 Dec; 18(6):592-5. PubMed ID: 7198328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Murphy GP; Slack NH; Mittelman A
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate.
    Soloway MS; deKernion JB; Gibbons RP; Johnson DE; Loening SA; Pontes JE; Prout GR; Schmidt JD; Scott WW; Chu TM; Gaeta JF; Slack NH; Murphy GP
    J Urol; 1981 May; 125(5):664-7. PubMed ID: 7230336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine.
    Catane R; Kaufman J; Mittelman A; Murphy GP
    J Urol; 1977 Mar; 117(3):332-5. PubMed ID: 839597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine phosphate (Estracyt) treatment of T3-T4 prostatic carcinoma.
    Veronesi A; Zattoni F; Frustaci S; Galligioni E; Tirelli U; Trovó G; Tumolo S; Merlo A; Artuso G; Cosciani-Cunico S; Grigoletto E
    Prostate; 1982; 3(2):159-64. PubMed ID: 7088731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area.
    Soloway MS; Beckley S; Brady MF; Chu TM; deKernion JB; Dhabuwala C; Gaeta JF; Gibbons RP; Loening SA; McKiel CF; McLeod DG; Pontes JE; Prout GR; Scardino PT; Schlegel JU; Schmidt JD; Scott WW; Slack NH; Murphy GP
    J Urol; 1983 Jan; 129(1):56-61. PubMed ID: 6338251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chemotherapy of prostatic adenocarcinoma.
    Torti FM; Carter SK
    Ann Intern Med; 1980 May; 92(5):681-9. PubMed ID: 6992675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of estramustine phosphate (estramustine, Estracyt) in Norway 1972-1981. An example of the irrational use of an expensive treatment].
    Fosså SD; Hovind OB; Hillestad B
    Tidsskr Nor Laegeforen; 1984 Mar; 104(7):482-4. PubMed ID: 6729780
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship of prior hormonal therapy to subsequent estramustine phosphate treatment in advanced prostatic cancer.
    Slack NH; Wajsman Z; Mittelman A; Bruno S; Murphy GP
    Urology; 1979 Dec; 14(6):549-54. PubMed ID: 390810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
    Mittelman A; Catane R; Murphy GP
    Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
    Vahlensieck W; Wegner G
    Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estramustine phosphate--hormone, chemotherapeutic agent, or both?
    Walzer Y; Oswalt J; Soloway MS
    Urology; 1984 Jul; 24(1):53-8. PubMed ID: 6539998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
    Herr HW
    J Urol; 1982 Mar; 127(3):462-5. PubMed ID: 7062419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
    Pouillart P; Bretaudeau B; Palangie T; Jouve M; Garcia-Giralt E; Asselain B
    Bull Cancer; 1982; 69(5):434-42. PubMed ID: 6891903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt).
    Gunnarsson PO; Forshell GP; Fritjofsson A; Norlén BJ
    Scand J Urol Nephrol; 1981; 15(3):201-5. PubMed ID: 7323739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate.
    Benson RC; Wear JB; Gill GM
    J Urol; 1979 Apr; 121(4):452-4. PubMed ID: 439216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate.
    Mittelman A; Shukla SK; Murphy GP
    J Urol; 1976 Apr; 115(4):409-12. PubMed ID: 1263317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
    Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
    Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Estracyt, new therapeutic agent for cancer of the prostate].
    Bouffioux C; de Leval J
    Rev Med Liege; 1980 Dec; 35(24):865-70. PubMed ID: 7209203
    [No Abstract]   [Full Text] [Related]  

  • 20. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
    Toulouse J; Jung JL; Bittard M
    J Urol (Paris); 1984; 90(1):27-33. PubMed ID: 6725973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.